Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    19720923 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Enrolling by invitation Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Conditions: HER2/Neu Positive;   HLA-A2 Positive Cells Present;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer
Interventions: Biological: HER-2/neu Peptide Vaccine;   Other: Laboratory Biomarker Analysis

Study has passed its completion date and status has not been verified in more than two years.